让创新不再“卡在路上”，山东医药改革在补哪块短板？

Core Viewpoint - The article highlights the persistent challenge in the pharmaceutical innovation sector, where numerous research outcomes fail to translate into market-ready drugs due to inefficiencies in the conversion chain from research to application [1] Group 1: Reform Initiatives - The Shandong provincial government has issued 29 reform measures aimed at addressing the bottlenecks in the pharmaceutical industry, signaling a shift from isolated efforts by companies to a collaborative approach involving institutional support [1][2] - The reform emphasizes a full-chain reconstruction, where various departments such as technology, drug regulation, health, and insurance work together rather than in silos, facilitating a more integrated innovation process [3] Group 2: Role of Regulatory Bodies - Regulatory bodies are transitioning from mere overseers to "innovation partners," engaging early in the development process to guide clinical trial designs and registration pathways, thereby reducing the trial and error costs for companies [4] - This shift does not imply a relaxation of regulations but rather a more proactive and professional approach to ensure clarity in standards and processes, which is crucial for the successful commercialization of innovations [4] Group 3: Clinical and Insurance Integration - The article stresses that the ultimate goal of pharmaceutical innovation is not just the existence of technology but its actual application in patient care, addressing the issues of accessibility and willingness to use new treatments [5] - Shandong's reforms aim to streamline the entry of innovative drugs into clinical settings and enhance their market availability through improved mechanisms for hospital drug procurement and insurance negotiations, ensuring sustainable usage and pricing [5][6]